Morningstar Investor users sign in here.
We’re currently having some problems with our data feed. We apologise for any inconvenience.

Company Profile

  • Business description

    Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

  • Contact

    2223 Avenida De La Playa
    Suite 105
    La Jolla CA 92037
    USA

    T: +1 858 240-1200

    E: ir@equilliumbio.com

    https://www.equilliumbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    44

Stocks News & Analysis

stocks

Going into earnings, Is Apple stock a buy, a sell, or fairly valued?

Watching iPhone revenue, gross margins, and services growth.
stocks

One of the hottest shares on the ASX reports strong growth

Should investors chase this growth story or are they overvalued after the surge in the shares.  
stocks

Diverging value in Australia's real estate sector

One stock dominates Australia's A-REIT index and it has had an incredibly strong year. Our analysts see value elsewhere.

Markets

Index
Last price
Change
% Change
All Ordinaries 8,153.40 59.10 0.73%
CAC 40 7,517.68 90.66 1.22%
DAX 40 18,417.55 118.83 0.65%
Dow JONES (US) 40,589.34 654.27 1.64%
FTSE 100 8,285.71 99.36 1.21%
HKSE 17,021.31 16.34 0.10%
NASDAQ 17,357.88 176.16 1.03%
Nikkei 225 37,667.41 202.10 -0.53%
NZX 50 Index 12,349.47 46.80 -0.38%
S&P 500 5,459.10 59.88 1.11%
S&P/ASX 200 7,921.30 60.10 0.76%
SSE Composite Index 2,890.90 4.16 0.14%

Market Movers

Name
Last price
Change
% Change
Bellevue Gold Ltd BGL 1.44 0.40 -21.58%
Argosy Minerals Ltd AGY 0.05 0.01 41.18%
Red 5 Ltd RED 0.38 0.02 -5.06%
Pilbara Minerals Ltd PLS 2.98 0.11 3.83%
Droneshield Ltd DRO 1.40 0.09 -6.04%
Sayona Mining Ltd SYA 0.03 0.00 0.00%
Core Lithium Ltd CXO 0.10 0.01 6.59%
Zip Co Ltd ZIP 1.78 0.04 -1.93%
South32 Ltd S32 2.98 0.07 2.41%
Telstra Group Ltd TLS 3.85 0.01 0.26%